INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Friday, October 17, 2025**
Time:	8:00 am Pacific Time
Location:	Zoom Teleconference
Institution:	The Angeles Clinic and Research Institute, Los Angeles, CA
Principal Investigator:	**Inderjit Mehmi, MD**
Protocol:	Replimune, Inc., **RP2-202**
NCT Number:	NCT06581406
Meeting Type:	Continuing Review of Protocol and Site
Title:	A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma

1. Call to order:

The Meeting was called to order at 8:02 am Pacific Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present was one Institutional Representative and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for RP2 since it is based on a recombinant herpes simplex virus-1 administered in a clinical setting. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of RP2 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Institutional Representative confirmed that the Biohazard Sign is posted on the dosing room door when a subject is being dosed and is removed after dosing is completed. The Committee recommended that a photo of the posted Biohazard Sign on the dosing room door be provided to IBC Services.
2. The Institutional Representative confirmed that the Biohazard Sign is posted on the door to the preparation room and on the biological safety cabinet (BSC).
3. The Committee noted that Slide 16 in the Photos document is mislabeled as it shows a dosing room rather than the storage room. The Committee recommended that the label on the photo be revised to accurately reflect the location shown.
4. The Institutional Representative confirmed that no subjects have been dosed since the Continuing Review Report Form was submitted to IBC Services.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representative.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 8:14 am Pacific Time.